Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T21:43:24.999Z.
Calculation as of: 2026-10-06T21:43:24.999Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc4657557541446f84d9f7820ae4f915e84790dbce56ed6e08d87a0074ca8553
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$3.38B
EV/FCF Ratio
17.60x
TTM Avg
24.95x
3Y Avg
51.13x
5Y Avg
51.13x
Market Cap
$3.19B
EV/FCF Ratio
49.92x
TTM Avg
51.28x
3Y Avg
51.28x
5Y Avg
50.61x
Market Cap
$3.48B
EV/FCF Ratio
N/A
TTM Avg
10.34x
3Y Avg
10.32x
5Y Avg
10.32x
Market Cap
$3.12B
EV/FCF Ratio
N/A
TTM Avg
34.40x
3Y Avg
34.40x
5Y Avg
34.40x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | $3.31B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.30B | 34.64x | 28.10x | 179.80x | 179.80x |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 17.60x | 24.95x | 51.13x | 51.13x |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 49.92x | 51.28x | 51.28x | 50.61x |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | N/A | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A | 10.34x | 10.32x | 10.32x |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A | 34.40x | 34.40x | 34.40x |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | 102.71x | 176.05x | 209.85x | 209.85x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
